Merck: EU approves urothelial carcinoma treatment

(CercleFinance.com) - Merck has announced that the European Commission has approved Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.


This approval follows the recommendations of the European Oncology and Urology Societies, and is based on positive results from a Phase 3 trial.

This treatment showed significant improvements in overall survival and progression-free survival compared with platinum-based chemotherapy.

Keytruda is now approved in all 27 EU member states, as well as in Iceland, Liechtenstein, Norway and Northern Ireland.


Copyright (c) 2024 CercleFinance.com. All rights reserved.